Acute Management of Appetite-related Disorders

PH284 is an early-stage investigational synthetic neuroactive steroid with potential for the acute management of appetite-related disorders. In an exploratory Phase 2A randomized, double blind, placebo controlled clinical study (n=40) in patients diagnosed with cachexia due to terminal cancer conducted at the National Institute of Cancerology and National Institute of Nutrition Mexico City, Mexico, patients were dosed 4 times per day, 30 minutes before each major meal with 0.8 µg PH284 nasal spray (n=20) or placebo nasal spray (n= 20) during 7 consecutive days. At the end of the 7-day treatment period, PH284-treated patients showed a significant increase in the subjective feeling of hunger (appetite), an increase in body weight and animproved quality of life, as compared with the placebo-treated group. No adverse side effects were reported.